In addition, GLP-1 RAs are particularly effective in reducing HbA1c, which is especially relevant as HbA1c levels 6.5% have been shown to be associated with increased incidence of microvascular complications [69] while it is challenging to achieve HbA1c levels 30 ml/min/1.73 m 2 [2], with a GLP-1 RA as the preferred agent if additional therapy is needed for glycemic control
Cardiovascular outcome trials CVOTs have emerged as a pivotal component of assessing the impact of GLP-1 receptor agonists on cardiovascular health (35)
Some people experience diarrhea, bloating, and feeling too full, which can worsen when they increase their fiber intake too quickly
An ultrasound at baseline is not required by guidelines but may be reasonable in high-risk patients
When these cells detect the presence of nutrients from the food weve eaten, they release GLP-1
For patients with Hashimoto's disease considering GLP-1 receptor agonist therapy for appropriate metabolic indications, several safety considerations warrant careful attention